By clicking “View Open Positions”, you acknowledge and consent to your personal information being transferred cross-border to Pivotal Headquarters in Hong Kong. For more details, please refer to the Recruitment Privacy Policy.
Gracell
THERAPEUTIC AREA
Cell therapy
YEAR INVESTED
2023
STAGE
IPO'd in 2021; acquired by AstraZeneca in 2024
WEBSITE
Gracell Biotechnologies is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapy. The company is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates to overcome major industry challenges that persist with conventional CAR-T therapies.
SHANGHAI
Suite 2001, YI FUNG PLACE
99 West Ziyun Road
Changning District
Shanghai 200051, China
HONG KONG
17th Floor
AIRSIDE
2 Concorde Road, Kai Tak
Hong Kong SAR
SAN FRANCISCO
501 2nd Street, Suite 200
San Francisco, CA 94107
United States
中文
English
